Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (141-150 of 184) with videos related to

Pageof 19
Sort By:
Gynecologic Oncology|July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
Journal of Ovarian Research|June 27, 2023
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancerGoutam Dey, Rashmi Bharti, Chad Braley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|February 19, 2011
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group studyJohn Farley, Michael W Sill, Michael Birrer, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Gynecologic Oncology|December 1, 2015
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyLisa M Landrum, William E Brady, Deborah K Armstrong, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Gynecologic Oncology|July 4, 2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology GroupMark A Morgan, Kathleen M Darcy, Peter G Rose, et al.
Frontiers in Oncology|February 27, 2024
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancerDenise Uyar, Chad M Michener, Erin Bishop, et al.
Journal of Ovarian Research|November 19, 2019
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancerElizabeth V Connor, Caner Saygin, Chad Braley, et al.
Pageof 19

Showing results (141-150 of 184) with videos related to

Sort By:
Pageof 19
Gynecologic Oncology|July 17, 2012
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Kathleen M Darcy, et al.
Journal of Ovarian Research|June 27, 2023
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancerGoutam Dey, Rashmi Bharti, Chad Braley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group StudyWilliam E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology|February 19, 2011
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group studyJohn Farley, Michael W Sill, Michael Birrer, et al.
Cancer|January 22, 2009
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group studyKristin K Zorn, Chunqiao Tian, William P McGuire, et al.
Gynecologic Oncology|December 1, 2015
A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyLisa M Landrum, William E Brady, Deborah K Armstrong, et al.
Gynecologic Oncology|June 21, 2018
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)John K Chan, William Brady, Bradley J Monk, et al.
Gynecologic Oncology|July 4, 2008
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology GroupMark A Morgan, Kathleen M Darcy, Peter G Rose, et al.
Frontiers in Oncology|February 27, 2024
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancerDenise Uyar, Chad M Michener, Erin Bishop, et al.
Journal of Ovarian Research|November 19, 2019
Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancerElizabeth V Connor, Caner Saygin, Chad Braley, et al.
Pageof 19